Bottom line
- Total investment $60K – $298K including a $55K franchise fee, 7.0% ongoing royalty.
- Average unit revenue of $279K/year.
- Rated STRONG with a risk score of 52/100. SBA loan default rate of 0.0% across 4 loans (below the industry average).
Item 1 · who you're contracting with
The Franchisor
Yale framework · single-unit ROIC
Returns Analysis
Pulls Item 7 (investment) and Item 19 (revenue) from this brand's FDD into the Yale unlevered-ROIC formula. Override any input to stress-test it against your own assumptions.
The model · Yale framework
What would one Any Lab Test Now unit return on the cash you put in?
Unlevered ROIC · per unit
28%
Below typical band (30–60%)
Levered LBO scenario · Yale Crease Capital framing
What would 25 Any Lab Test Now units return on equity?
Equity IRR · 5-yr
49.9%
7.57× MOIC
Year-1 DSCR
1.88×
EBITDA ÷ debt service
Equity required
$781K
on $3.9M purchase
Total debt
$3.1M
SBA $2.0M + senior + seller note
Overview
About
Franchisees operate clinical laboratory testing centers offering direct-to-consumer lab work (blood tests, drug screening, STI testing, wellness panels) without physician orders. Day-to-day operations involve patient check-in/specimen collection, CLIA compliance management, operating phlebotomy services, managing lab partnerships, and marketing locally to capture walk-in and corporate wellness clients.
Item 7 · what it costs
The Vitals
Item 19
Financial Performance
Item 20 · unit dynamics
The Growth Chart
Year-over-year franchised unit counts and net change. Source: FDD Item 20.
Item 12 · 32 states reported
The Territory Map
FDD Item 12 reports the state count, but the specific list isn't in our current data. The map will appear once we re-extract from the FDD or enough franchisee contacts are available.
32
states with franchisees (per FDD Item 12)
Government records
SBA Loan Data
Aggregated from SBA 7(a) loan disclosures, public data unique to FranchiseVerdict.
FranchiseVerdict rating + FDD Items 3, 5, 6, 12, 17
Risk & Legal
Modest growth, regulatory history, and complete absence of earnings disclosure create material uncertainty around unit economics and return potential.
Score breakdown · what drove the 52 / 100 rating
- 01MEDNo Item 19 (Average Unit Volume) disclosed despite $278,763 reported revenue — inability or unwillingness to substantiate earnings claims
- 02MINOR7.2% YoY unit growth is modest for a healthcare services franchise; 244 units suggests potential market saturation or franchisee underperformance
- 03MINOR2012-2013 Virginia securities violation and settlement indicate regulatory compliance issues; former CEO misconduct raises governance concerns
- 04MEDHigh initial investment ($60K-$298K) combined with 7% royalty plus $500 minimum monthly fee creates significant fixed cost burden relative to undisclosed net profitability
- 05MINORWide investment range ($238K spread) suggests inconsistent territory economics or lack of standardization in franchise model
Severity inferred from the FDD text · not a regulatory classification
FDD Items 5, 6, 12, 17 · continued from Risk & Legal
Contract & Territory Detail
Item 11
Training & Operations
Item 20
Franchisee Contacts
Phone numbers extracted directly from this brand's FDD Item 20. After purchase, you'll also receive a list of validation questions tailored to this brand.
Franchisee contacts
97 numbers
One-time purchase · CSV download · Validation questions included
FDD download
Any Lab Test Now · FDD (2025) PDF